Lumida
/LNSR
⌘K
LENSAR Inc

LENSAR Inc

LNSR
$7.60USD↓-5.59%-0.45 today

MARKET CAP

93.4M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$8 – $8

52W RANGE

$5
$13

AI Summary

Stalk
Sell NowMedium

LNSR remains in a Stage 4 decline with lower highs and lower lows driving a medium-term bearish bias. Short-term conditions are favorable for selling as price tightly tracks below declining EMAs near resistance. Long-term trend remains structurally bullish per upstream analysis but is overshadowed by current selling pressure. With no mean reversion permission and absent exhaustion signals, executing a sell now is recommended.

  • ↑Recurring revenue grew 9% YoY to $12.6M, now 94% of total sales
  • ↑US cataract market share hit 23.4%, up 4.3% since Ally rollout
  • ↓System sales fell to $0.8M in Q1 from $2.6M a year ago
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Lensar, Inc. (NASDAQ: LNSR) is a medical technology company that specializes in advanced laser systems for ophthalmic surgery, with a particular focus on cataract procedures. The company is positioned within the growing ophthalmic market, leveraging its innovative Ally robotic laser cataract system to improve surgical accuracy and patient outcomes. Following a terminated merger attempt with Alcon, Lensar is in a recovery phase, focusing on strengthening its market presence and capitalizing on the growing demand for precision in cataract surgeries.

Bull says

  • ↑Recurring revenue grew 9% YoY to $12.6M, now 94% of total sales
  • ↑US cataract market share hit 23.4%, up 4.3% since Ally rollout
  • ↑Installed base reached 205 systems with 11 in backlog, driving 54K Q1 procedures
  • ↑Regulatory cleared in Europe and Taiwan, with international shipments pending
  • ↑Procedure volumes climbed to ~54K in Q1, reflecting strong demand
  • ↑Favorable growth and dividend factors underpin long-term resilience

Bear says

  • ↓System sales fell to $0.8M in Q1 from $2.6M a year ago
  • ↓Recorded a $36.3M net loss with margin pressure and rising expenses
  • ↓Elevated leverage risk and weak profitability factors threaten stability
  • ↓Price-to-earnings at –8.7 signals valuation concerns
  • ↓Intense competition from Alcon, Bausch + Lomb and J&J may erode share
  • ↓Reimbursement cuts and placement disruptions pose adoption headwinds

Earnings Call · Q3 2024 · Mgmt. Guidance

Updated 08-18-2026bullish

Transcript signals

Bull points

  • 24 new ally systems, an outstanding 118% increase over what had been a strong third quarter of 2023 and a 41% increase over the second quarter of 2024, driven in part by very solid performance outside of the United States, where we sold 11 Ally systems following mid-third quarter regulatory clearances in Europe, Switzerland, and Taiwan
  • We achieved $13.5 million of revenue in the third quarter, an increase of over 38% from the third quarter of last year, which, as I just described, was attributable to robust growth in system placements, including 11 OUS system sales
  • procedure volumes increasing 29% over the third quarter of 2023 and US procedures increasing 22% year over year

Bear points

  • Net loss for the quarter was $1.5 million, or a 13-cent loss per common share, compared to $2.6 million net income, or a 13-cent gain per common share in the third quarter of 2023.
Read full transcript analysis ›